Health Investment

Aurinia Pharmaceuticals Inc.

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market.

Aurinia Pharmaceuticals Inc.

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. Its lead drug, Voclosporin, is a novel calcineurin inhibitor. Many members of Aurinia’s current leadership team are former senior managers of Aspreva Pharmaceuticals (“Aspreva”), which Galenica acquired for C$915 million in 2008. While at Aspreva, this management team executed one of the largest and most important lupus nephritis studies ever conducted, called the Aspreva Lupus Management Study (“ALMS”), which resulted in the emergence of mycophenolate mofetil (“CellCept®”) as a new standard treatment for patients suffering from this devastating and potentially fatal disease. Aurinia will develop Voclosporin in combination with CellCept® for the treatment of lupus nephritis, a life threatening kidney disease. Aurinia has development and commercialization partners in Canada, Israel, South Africa and Greater China.

More information is available at www.auriniapharma.com.